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Background: Insulin resistance (IR) is closely correlated with cardiovascular disease (CVD). Retinol-binding protein
4 (RBP4) is a novel adipokine that modulates the action of insulin in various diseases. This study addressed the
relationship between RBP4 and IR in newly diagnosed essential hypertension.
Methods: Serum RBP4, anthropometric and metabolic parameters were determined in 267 newly diagnosed
essential hypertensive patients not taking antihypertensive medications. The patients along with 64 control (NC)
normotensive and lean subjects paired by age and sex were divided into two groups depending on body mass
index (BMI), hypertension with obesity (HPO) and hypertension without obesity (HP).
Results: A striking difference was observed in RBP4 levels between the HP and NC groups. Significantly higher
levels were noted in the HP group compared with the NC group; slightly, but not significantly, lower levels were
observed in the HPO group compared with the HP group. After adjusting for BMI, WC and WHR, a modestly
linear relationship was observed between RBP4 levels and SBP (r = 0.377; p = 0.00), DBP (r = 0.288; p = 0.00) and
HOMA-β(r = 0.121; p = 0.028). Multiple stepwise regression analysis showed that SBP, WHR and drinking were
independently related with serum RBP4 levels.
Conclusions: The results of this study indicated that RBP4 levels were increased in naive hypertensive patients;
however, no differences were observed in obese or non-obese hypertensive subjects. Our data suggest for the first
time that RBP4 levels are significantly increased but do not contribute to the development of IR in newly diagnosed
hypertensive Chinese patients.
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Insulin resistance (IR) is one of the major characteristics
of cardiovascular disease (CVD). Abundant clinical and
epidemiologic evidence demonstrates a close relation-
ship between IR and hypertension [1]. Recent studies
have demonstrated that adipocytokines play important
roles in the pathogenesis of obesity and hypertension.* Correspondence: chenbing3@medmail.com.cn
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unless otherwise stated.Retinol-binding protein 4 (RBP4) is a novel adipokine
secreted by adipose tissue and the liver that contributes
to IR in animal models [2,3]. However, data in humans
have been controversial; serum RBP4 levels are report-
edly elevated with IR in patients with obesity [2,4] and
CVD [5,6], but other authors have failed to confirm
these findings [7-10]. In addition, antihypertensive medi-
cations were not excluded [10] in previous research des-
pite the fact that angiotensin receptor blockers (ARBs)
and calcium-channel blockers (CCBs) can influence
serum RBP4 levels [11,12] and IR [13-15]. Previous stud-
ies have revealed that RBP4 is closely correlated withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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To date, no studies have evaluated the relationship of
RBP4 with IR in largely drug-naive, newly diagnosed
hypertensive subjects and normotensive matched indi-
viduals. Therefore, in this study, we sought to determine
the associations among RBP4 and metabolic indices and
IR in newly diagnosed, untreated hypertension patients.
Subjects and methods
Study population
We consecutively selected 1400 subjects from the gen-
eral population who had undergone medical check-ups
at the Southwest Hospital Medical Center at the Third
Military Medical University from October 2012 to June
2013. After excluding 1069 of the 1400 subjects, a total
of 331 subjects were enrolled in our study. In total, 127
newly diagnosed hypertension subjects without obesity
(84 men, 43 women, 48.2 ± 8.6 years old, HP group), 140
newly diagnosed patients with hypertension and obesity
(97 men, 43 women, 47.7 ± 8.8 years old, HPO group)
and 64 normal control subjects (44 men, 20 women,
46.9 ± 7.6 years old, NC group) participated in the study.
The diagnosis of hypertension was based on the World
Health Organization criteria (1999) [17]. These subjects
exhibited stable body weight for at least 3 months prior
to testing. The subjects enrolled in the analysis met the
following inclusion criteria: (1) age 20 years old or older
and younger than 65 years old; (2) fasting blood glucose
(FBG) < 6.1 mmol/L and without diabetes or thyroid dis-
ease; (3) not taking antihypertensive, antidiabetic or lipid-
lowering medications; (4) no clinical symptoms or signs of
infection; no liver, kidney or heart disorders or other crit-
ical diseases; and no fractures, osteoporosis or tumors; (5)
no target organ damage; and (6) not pregnant or lactating.
This study was approved by the ethics committee of the
Third Military Medical University, and all of the subjects
provided written informed consent. Medical histories, in-
cluding smoking and drinking habits, were obtained from
the subjects.
Anthropometric and blood pressure measurements and
definitions
All of the participants were required to fast overnight
(8–10 h) before the physical examination. Anthropomet-
ric parameters were recorded followed by blood pressure
measurements. Then, medical examinations and blood
collections were conducted. Blood pressure was mea-
sured three times, each 2 min apart on the upper arm
using a mercury sphygmomanometer (YUYUE Medical
Equipment & Supply CO., LTD., Jiangsu province, China)
in a seated, resting position after 10 min of rest; the
mean of the three measurements was used for the statis-
tical analysis. Anthropometric parameters, including
weight, height and hip and waist circumference (WC),were measured using the International Collaborative
Study on Hypertension in Blacks (ICSHIB) standardized
protocol [18]. Body mass index (BMI) was calculated as
body weight in kilograms divided by the square of
height (m2). The waist-to-hip ratio (WHR) was calcu-
lated as the waist to hip circumference.
We defined current alcohol consumption as more than
1 drink of any type per month and not currently drink-
ing as less than 1 drink of any type per month [19].
Smokers were defined as having smoked more than 100
cigarettes in one’s lifetime and having smoked at least
one cigarette daily for 6 months by the time of the inter-
view [20]. Obesity was defined as body mass index
(BMI) ≥ 25 kg/m2 as suggested by the WHO Western
Pacific Regional Office [21]. Hypertension was defined
as a systolic blood pressure (SBP) ≥ 140 mmHg and/or a
diastolic blood pressure (DBP) ≥ 90 mmHg [17].
Experimental procedures and serum samples
Overnight fasting blood samples were collected in tubes
containing liquid EDTA; the samples were centrifuged
at −4°C and maintained at −80°C until assayed. A certi-
fied laboratory assessed metabolic parameters, including
fasting blood glucose (FBG), blood uric acid (UA), total
cholesterol (TC), triglycerides (TG), low-density lipopro-
tein C (LDL-C), high-density lipoprotein C (HDL-C) and
fasting insulin (FINS). FBG was assayed using the glu-
cose oxidase method. UA, TC, TG, LDL-C and HDL-C
concentrations were determined enzymatically. Serum
RBP4 levels were evaluated using a commercially avail-
able enzyme-linked immunosorbent assay (ELISA; R&D
Systems, Inc., Minneapolis, MN, USA). The intra-assay
coefficients of RBP4 were less than 10%, and the interas-
say coefficients were less than 15%. The linear ranges of
the assays were 1.0 to 300 μg/ml for RBP4.
The homeostasis model assessment of IR (HOMA-
IR) as an indicator of IR and the homeostasis model
assessment of β-cell insulin secretion (HOMA-β) were
calculated from FINS and FBG levels using the fol-
lowing equations: HOMA-IR = FINS (μU/mL) × FBG
(mmol/L)/22.5; and HOMA-β = (20 × FINS [μU/ml])/
(FBG [mmol/L - 3.5]) [22].
Statistical analysis
The experimental data were analyzed using SPSS soft-
ware (SPSS, Chicago, IL, USA), version 17.0. Continuous
variables are presented as means ± standard deviations,
and categorical variables are presented as absolute and
relative frequencies (%). Before the statistical analysis,
the data were subjected to normal distribution analysis
using the Kolmogorov-Smirnov test. Non-normally dis-
tributed data (TG, FINS, HOMA-IR and HOMA-β) were
converted by logarithmic transformation. Categorical
variables were compared using the chi-square test. The
Table 1 Clinical characteristics of study subjects
NC (n = 64) HP (n = 127) HPO (n = 140) p-value
Age (yr) 46.9 ± 7.6 48.2 ± 8.6 47.7 ± 8.8 0.602*
Sex (M/F) 97/43 84/43 44/20 0.852#
BMI (kg/m2) 22.2 ± 1.3 22.5 ± 1.7 27.8 ± 1.9ab 0.000*
WC (cm) 81.1 ± 5.4 83.0 ± 6.7c 94.7 ± 6.0ab 0.000*
WHR 0.88 ± 0.05 0.90 ± 0.05c 0.94 ± 0.05ab 0.000*
SBP (mmHg) 116.5 ± 11.4 151.7 ± 11.7a 155.8 ± 14.7ad 0.000*
DBP (mmHg) 74.5 ± 7.7 97.0 ± 9.4a 98.8 ± 11.4a 0.000*
UA (µmol/l) 294.2 ± 67.7 323.0 ± 78.8c 384.8 ± 91.4ab 0.000*
TG (mmol/l) 1.39 ± 0.65 1.93 ± 1.07a 2.43 ± 1.27ab 0.000*
TC (mmol/l) 5.31 ± 0.95 5.38 ± 0.92 5.40 ± 0.97 0.658*
LDL-C (mmol/l) 2.53 ± 0.60 2.70 ± 0.58 2.72 ± 0.63 0.176*
HDL-C (mmol/l) 1.60 ± 0.28 1.53 ± 0.33 1.42 ± 0.33ab 0.001*
FBG (mmol/l) 5.45 ± 0.42 5.42 ± 0.57 5.64 ± 0.56bc 0.003*
FINS (pmol/l) 8.4 ± 3.90 10.7 ± 3.57a 14.6 ± 5.40ab 0.000*
HOMA-IR 2.06 ± 1.06 2.60 ± 1.00a 3.66 ± 1.40ab 0.000*
HOMA-β 87.4 ± 32.7 119.7 ± 48.8a 149.5 ± 83.9a 0.000*
Smoking (%) 32.8% 37.0% 33.6% 0.788#
Drinking (%) 26.6% 34.7% 51.4%ab 0.001#
Data represent means ± SD or frequency (percentage).
TG, FINS and HOMA-IR were log transformed before analysis.
*Analysis of variance; # chi-squared test.
ap < 0.01 compared with NC.
bp < 0.01 compared with HP.
cp < 0.05 compared with NC.
dp < 0.05 compared with HP.
NC, normal control subject; HP, hypertension with obesity; HPO, HP
with obesity; BMI, body mass index; WC, Waist circumference; WHR,
waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure;
WHR, waist hip ratio; UA, uric acid; TG, triglyceride; TC, total cholesterol;
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol; FBG, fasting blood glucose; FINS, fasting plasma insulin; HOMA-IR,
HOMA-insulin resistance index; HOMA-β, HOMA β cell function index.
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ance (ANOVA). In addition, a post-hoc least-significant dif-
ference (LSD) test was used for equal variances assumed
variables, and Dunnett’s test was used for equal vari-
ances not assumed variables. Interrelationships between
variables were analyzed by Pearson correlation analysis.
Partial correlation analysis was performed to control for
body fat parameters. Multiple linear regression analysis
was performed using stepwise linear regression to cor-
rect the effects of the covariates and to test independent
factors. A p-value < 0.05 was considered to be statisti-
cally significant for all of the analyses.
Results
The three groups of subjects were well matched for age
and sex, and all of the subjects with hypertension were
naive to antihypertensive therapy. The clinical character-
istics of the study subjects are presented in Table 1. TC
and LDL-C did not differ among the three groups. The
HPO group displayed higher BMI, WC, WHR, SBP,
DBP, UA, TG, FINS, HOMA-IR, HOMA-β, drinking (all
p < 0.01) and FBG (p < 0.05) but lower HDL-C (p < 0.01)
than the NC group. The HPO group had higher BMI,
WC, WHR, UA, TG, FBG, FINS, HOMA-IR, drinking
(all p < 0.01) and SBP (p < 0.05) but lower HDL-C (p < 0.01)
than the HP group. The HP group had higher SBP, DBP,
TG, FINS, HOMA-IR, HOMA-β (p < 0.01), WC, WHR
and UA (p < 0.05) than the NC group.
As presented in Figure 1, serum RBP4 levels were sig-
nificantly increased in the hypertensive subjects (HP and
HPO groups) compared with the NC group (73.6 ±
18.3 μg/ml, 69.8 ± 19.9 μg/ml versus 42.4 ± 16.6 μg/ml,
both p < 0.01). However, a decreasing trend in serum
RBP4 concentrations was observed in the HPO group
compared with the HP group (69.8 ± 19.9 μg/ml versus
73.6 ± 18.3 μg/ml, p = 0.093), but the trend was not sta-
tistically significant. Bivariate correlation analyses were
performed to assess relationships between RBP4 levels
and anthropometric or metabolic parameters. RBP4 was
positively correlated with BMI (r = 0.108; p = 0.049), SBP
(r = 0.381; p = 0.00), DBP (r = 0.296; p = 0.00), TG (r =
0.127; p = 0.021), FINS (r = 0.116; p = 0.035), HOMA-IR
(r = 0.121; p = 0.027), and HOMA-β (r = 0.153; p = 0.005).
After adjusting for BMI, WC and WHR, positive correla-
tions between RBP4 and SBP (r = 0.377; p = 0.00), DBP
(r = 0.288; p = 0.00) and HOMA-β (r = 0.121; p = 0.028)
were still evident, but the correlations between RBP4 and
TG (r = 0.106; p = 0.055), FINS (r = 0.068; p = 0.219) and
HOMA-IR (r = 0.075; p = 0.177) disappeared. Using age,
sex, BMI, WC, WHR, SBP, DBP, UA, TC, TG, LDL-C,
HDL-C, FBG, FINS, HOMA-IR and HOMA-β as inde-
pendent variables, multiple stepwise regression analysis re-
vealed that SBP, WHR and drinking were independently
related to RBP4 levels (β = 0.397, −0.175, 0.181, all p < 0.05).The multiple regression equation was as follows: YRBP4 =
59.27 + 0.45XSBP ‐ 68.06XWHR + 8.01XDrinking (Table 2).
Discussion
Associations among RBP4 and markers of IR and
metabolic indices
Previous studies have yielded conflicting results regarding
the relationship between RBP4 and IR [23,24]. Animal
models and some human research have reported that
RBP4 contributes to IR [2-4]. However, other relationships
have been inconsistently demonstrated. Von Eynatten
et al. revealed no significant correlations between RBP4
levels and BMI or HOMA-IR in 143 patients with coron-
ary artery disease [25]. Similarly, Shim et al. found that
RBP4 was not associated with IR or metabolic indices in
308 non-diabetic hypertensive patients, but this report did
not exclude the influence of antihypertensive medications
[10]. Therefore, it is worth exploring the clinical signifi-
cance of RBP4 in newly diagnosed, untreated hypertension
patients.
Figure 1 Serum RBP4 levels in NC, HP and HPO groups. ap < 0.01
compared with NC.
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investigated the relationships between RBP4 levels and
relevant factors. Given that adipokine expression may be
affected by sex hormones, a study reported that increases
in RBP4 levels following blood pressure increases exclu-
sively occurs in women and not men [9]. We compared
serum RBP4 levels between genders, but no sex difference
was observed. We found that HOMA-IR was significantlyTable 2 Linear and multiple regression analysis of
anthropometric and metabolic parameters associated
with RBP4 in subjects studied
Simple Multiple
Variable Estimate p-value Estimate p-value
BMI (kg/m2) _ _ _ _
WC (cm) _ _ _ _
WHR _ _ −0.175 0.003
SBP (mmHg) 0.377 0.000 0.397 0.000
DBP (mmHg) 0.288 0.000 _ _
UA (µmol/l) 0.014 0.796 _ _
TG (mmol/l) 0.106 0.055 _ _
TC (mmol/l) 0.014 0.802 _ _
LDL-C mmol/l) 0.031 0.612 _ _
HDL-C (mmol/l) 0.067 0.268 _ _
FBG (mmol/l) 0.045 0.416 _ _
FINS (pmol/l) 0.068 0.219 _ _
HOMA-IR 0.075 0.177 _ _
HOMA-β 0.121 0.028 _ _
Drinking _ _ 0.181 0.002
In multiple regression analyses, p-values were calculated after adjusting for
BMI, WC and WHR.
TG, FINS, HOMA-IR and HOMA-β were log transformed before analysis.elevated in the HP group compared with NC group and
rapidly increased along with obesity in the HPO group.
RBP4 was positively correlated with SBP, DBP, TG, FINS,
HOMA-IR and HOMA-β; however, the correlation be-
tween RBP4 and TG, FINS or HOMA-IR disappeared
after controlling for body fat parameters.
In present study, we found that serum RBP4 levels
were significantly increased in the hypertensive subjects
but do not contribute to IR after excluding the con-
founders of obesity. These results are consistent with
those identified in previous reports [10,23] but inconsist-
ent with the original report of the contribution of RBP4
to IR [2-4]. RBP4 levels were slightly positively associ-
ated with insulin secretion (HOMA-β), consistent with
Li L et al.’s previous report [26]. Insulin sensitivity and
serum insulin concentrations are mutually related, and
Burattini et al. [27] reported that insulin clearance was
decreased in hypertensive patients but not affected by
metabolic syndrome. Decreased insulin clearance is an-
other regulatory mechanism, in addition to increased in-
sulin secretion, that compensates for insulin resistance.
Interestingly, alcohol consumption independently influ-
ences RBP4, and we hypothesize that chronic ethanol
consumption disrupts glucose homeostasis and is associ-
ated with the development of IR. In addition, hyperten-
sion associated with IR is characterized by an infiltration
of macrophages into adipose tissues as well as changes
in the expression of adipocytokines.Relationship between RBP4 and hypertension
Previous research indicates that RBP4 is a possible pre-
dictor of CVD [28,29]. Alkharfy et al. suggested that
RBP4 might serve as an independent predictor of CVD
in 284 women with good health, obesity, diabetes, obes-
ity and diabetes or CVD [28]. In our results, we found
that RBP4 levels were higher in hypertension patients
than in normotensive, normal-weight patients. RBP4 was
strongly correlated with SBP and DBP, and the former
was an independently correlated factor of RBP4. Similar
findings have been reported previously. Solini et al. re-
ported that RBP4 levels were significantly increased in
35 untreated essential hypertensive women compared
with in 35 normotensive lean women, and RBP4 levels
were strongly and directly correlated with SBP and DBP
values in all of their subjects [29].Conclusions
Our study population, which contained a sufficient num-
ber of subjects, was strictly matched for age and sex,
thus likely excluding the influence of related metabolic
alterations on RBP4 levels. In summary, for the first
time, we have demonstrated that serum RBP4 levels
were significantly increased, but RBP4 did not appear to
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diagnosed hypertensive Chinese patients.
There were also some limitations to our study. Our
study subjects consisted of men and women of Chinese
ethnicity; hence, the generalizability of our study to
other ethnicities is unknown [30,31]. Although several
potential risk factors for CVD were included in our ana-
lysis, the role of some unknown or unmeasured con-
founders cannot be excluded. We did not perform oral
glucose tolerance tests or glucose clamp studies to deter-
mine insulin resistance because of condition limitations.
This finding should be investigated further in experi-
mental follow-up studies.
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